{"DataElement":{"publicId":"5036920","version":"1","preferredName":"Person Recovered or Resolved Prior Treatment Regimen Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A response to determine patient eligibility for clinical trial participation regarding the resolution of adverse events from prior therapy.","longName":"AE_REC_PR_TX_IND","context":"Theradex","contextVersion":"1","DataElementConcept":{"publicId":"3244787","version":"1","preferredName":"Person Recovered or Resolved Prior Treatment Regimen Clinical Trial Eligibility Criteria","preferredDefinition":"information related to a person's recovery from prior therapy as an elements of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial.","longName":"2236731v1.0:3244785v1.0","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2236731","version":"1","preferredName":"Person","preferredDefinition":"A human being.","longName":"C25190","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Person","conceptCode":"C25190","definition":"A human being.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9FC6DF7-66EB-4CAB-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-20","endDate":null,"createdBy":"UMLLOADER_MAGE","dateCreated":"2005-06-20","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3244785","version":"1","preferredName":"Recovered or Resolved Prior Treatment Regimen Clinical Trial Eligibility Criteria","preferredDefinition":"One of the possible results of an adverse event outcome that indicates that the event has improved or recuperated.:Earlier in time or order.:A treatment plan that specifies the dosage, the schedule, and the duration of treatment.:Elements of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial.","longName":"C49498:C25629:C15697:C16112","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Recovered from Adverse Event","conceptCode":"C49498","definition":"One of the possible results of an adverse event outcome that indicates that the event has improved or recuperated.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Prior","conceptCode":"C25629","definition":"Earlier in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Clinical Trial Eligibility Criteria","conceptCode":"C16112","definition":"Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A5C4AB2A-42ED-871F-E040-BB89AD433127","latestVersionIndicator":"Yes","beginDate":"2011-06-15","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-06-15","modifiedBy":"ONEDATA","dateModified":"2011-06-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A5C4AB2A-42FE-871F-E040-BB89AD433127","latestVersionIndicator":"Yes","beginDate":"2011-06-15","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-06-15","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3298541","version":"1","preferredName":"Yes No Not Applicable Code Indicator","preferredDefinition":"Indicator to represent a response of Yes, No, or Not Applicable._The affirmative response to a question or activity._The non-affirmative response to a question._Determination that a value is not relevant in the current context._A system of numbered categories for representation of data.","longName":"YES_NO_NA_CD_IND","context":"CCR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"1","maxLength":"1","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"X","valueDescription":"Not applicable","ValueMeaning":{"publicId":"2581003","version":"1","preferredName":"Not applicable","longName":"2581003v1.00","preferredDefinition":"Determination of a value is not relevant in the current context.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0978-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-31","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-12-31","modifiedBy":"CLOHNES","dateModified":"2023-11-09","changeDescription":null,"administrativeNotes":"2023.3.6 Added Alt VM-COG. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C223-0627-E040-BB89AD432C31","beginDate":"2002-02-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"},{"value":"N","valueDescription":"No","ValueMeaning":{"publicId":"2559515","version":"1","preferredName":"No","longName":"2559515","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B588-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"GDEEN","dateModified":"2024-01-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C22D-0627-E040-BB89AD432C31","beginDate":"2002-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"},{"value":"Y","valueDescription":"Yes","ValueMeaning":{"publicId":"2560453","version":"1","preferredName":"Yes","longName":"2560453","preferredDefinition":"The affirmative response to a question or activity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B932-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CLOHNES","dateModified":"2023-09-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C237-0627-E040-BB89AD432C31","beginDate":"2002-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3298540","version":"1","preferredName":"Yes No Not Applicable Code Indicator","preferredDefinition":"The affirmative response to a question or activity.:The non-affirmative response to a question.:Determination that a value is not relevant in the current context.:A system of numbered categories for representation of data.:An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","longName":"3298540v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Code","conceptCode":"C25162","definition":"A symbol or combination of symbols which is assigned to the members of a collection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Indicator","conceptCode":"C25180","definition":"An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B04AC04D-C1F2-0627-E040-BB89AD432C31","latestVersionIndicator":"Yes","beginDate":"2011-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CTMS:Clinical Trials Monitoring Service","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B04AC04D-C203-0627-E040-BB89AD432C31","latestVersionIndicator":"Yes","beginDate":"2011-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"MAESKEB","dateModified":"2016-01-20","changeDescription":"Created to support Theradex design of CRFs for NCI CCR trials","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"3876352","version":"1","longName":"Inclusion Criteria","context":"Theradex","ClassificationSchemeItems":[{"publicId":"10000494","version":"1","longName":"Prior Treatments","context":"Theradex"}]}],"AlternateNames":[{"name":"COG","type":"USED_BY","context":"COG"},{"name":"IE_IEORRES_INC01B","type":"Context Short Name","context":"Alliance"},{"name":"Alliance","type":"USED_BY","context":"Alliance"},{"name":"IE_IEORRES_INC02B","type":"Context Short Name","context":"Alliance"},{"name":"IE_IEORRES_INC03B","type":"Context Short Name","context":"Alliance"},{"name":"IE_IEORRES_INC04B","type":"Context Short Name","context":"Alliance"},{"name":"IE_IEORRES_INC05B","type":"Context Short Name","context":"Alliance"},{"name":"IE_IEORRES_INC06B","type":"Context Short Name","context":"Alliance"},{"name":"IE_IEORRES_TOXONGO","type":"OID, CCTG","context":"CCTG"}],"ReferenceDocuments":[{"name":"Theradex - 2","type":"Alternate Question Text","description":"Has patient recovered from adverse events attributable to previous treatment to less than or equal to grade 1, except for alopecia and sensory neuropathy less than or equal to grade 2?","url":null,"context":"Theradex"},{"name":"Has patient recovered from ad","type":"Preferred Question Text","description":"Has patient recovered from adverse events attributable to previous treatment to less than or equal to grade 1?","url":null,"context":"Theradex"},{"name":"Theradex - 1","type":"Alternate Question Text","description":"Have any adverse events from prior therapy resolved to baseline or grade less than or equal to 1 if resolvable at enrollment (with the exception of alopecia, neuropathy, and ototoxicity)?","url":null,"context":"Theradex"},{"name":"Theradex - 3","type":"Alternate Question Text","description":"Have toxicities related to prior treatment resolved to less than or equal to grade 1 or baseline with the exception of alopecia?","url":null,"context":"Theradex"},{"name":"Theradex - 4","type":"Alternate Question Text","description":"Has patient recovered to less than or equal to Grade 1 from any adverse events from any prior chemotherapy (other than alopecia)?","url":null,"context":"Theradex"},{"name":"Theradex - 6","type":"Alternate Question Text","description":"If patient has received prior medical therapy for their PN, has patient recovered from the acute toxic effects of all prior therapy to less than or equal to grade 1 CTCAEv4 before entering this study?","url":null,"context":"Theradex"},{"name":"Theradex - 7","type":"Alternate Question Text","description":"Have all greater than grade 1 adverse events related to prior therapies (chemotherapy, radiotherapy, and/or surgery) have resolved, except for alopecia?","url":null,"context":"Theradex"},{"name":"Theradex - 8","type":"Alternate Question Text","description":"Has patient recovered have from any acute toxicity related to prior therapy or surgery, to a grade 1 or less unless specified?","url":null,"context":"Theradex"},{"name":"Theradex - 9","type":"Alternate Question Text","description":"Has patient recovered from any acute toxicity related to prior therapy or surgery, to a grade 1 or less unless specified?","url":null,"context":"Theradex"},{"name":"Theradex - 10","type":"Alternate Question Text","description":"Is patient greater than or equal to 2 weeks from resolution (i.e., less than Grade 1 or at baseline) from AEs due to procedures performed or therapeutic agents administered?","url":null,"context":"Theradex"},{"name":"Theradex - 14","type":"Alternate Question Text","description":"Has patient recovered from any acute effects of any prior chemotherapy?","url":null,"context":"Theradex"},{"name":"Theradex - 15","type":"Alternate Question Text","description":"Has patient recovered to less than or equal to grade 1 NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 or stabilized from toxicity of prior chemotherapy or biologic therapy administered more than 4 weeks or 5 half-lives earlier, whichever is shorter?","url":null,"context":"Theradex"},{"name":"Theradex - 17","type":"Alternate Question Text","description":"Have all prior treatment related-toxicities resolved to CTCAE version 4.0 grade less than or equal to 1 (except alopecia) at the time of enrollment?","url":null,"context":"Theradex"},{"name":"Theradex - 12","type":"Alternate Question Text","description":"Have all prior anti-cancer treatment-related toxicities resolved to ≤ Grade 1 according to the Common Terminology Criteria for Adverse Events version 4 (CTCAE version 4.0; NCI, 2009) at the time of enrollment?","url":null,"context":"Theradex"},{"name":"Theradex - 11","type":"Alternate Question Text","description":"Have all greater than grade 1 adverse events related to prior therapies (chemotherapy, radiotherapy, and/or surgery) resolved, except for alopecia?","url":null,"context":"Theradex"},{"name":"Theradex - 13","type":"Alternate Question Text","description":"Has patient recovered to grade 1 from prior toxicity or adverse events?","url":null,"context":"Theradex"},{"name":"Theradex - 16","type":"Alternate Question Text","description":"Has patient recovered to grade 1 adverse events or to less than or equal to grade 2 alopecia and sensory neuropathy due to prior treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 19","type":"Alternate Question Text","description":"Has patient recovered to less than or equal to grade 1 adverse events or to less than or equal to grade 2 alopecia and sensory neuropathy due to prior treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 18","type":"Alternate Question Text","description":"Has patient recovered to less than or greater to grade 1 adverse events or to less than or equal to grade 2 alopecia and sensory neuropathy due to prior treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 20","type":"Alternate Question Text","description":"Have ongoing prior toxicities related to previous treatments recovered to less than grade 2 at the time of registration (with the exception of alopecia, grade 2 peripheral neuropathy or lymphopenia)?","url":null,"context":"Theradex"},{"name":"Theradex - 22","type":"Alternate Question Text","description":"Have all prior treatment related-toxicities resolved to CTCAE version 5.0 grade less than or equal to 1 (except alopecia) at the time of enrollment?","url":null,"context":"Theradex"},{"name":"Theradex - 21","type":"Alternate Question Text","description":"If patient has received prior medical therapy for their PN, has patient recovered from the acute toxic effects of all prior therapy to less than or equal to grade 1 before entering this study?","url":null,"context":"Theradex"},{"name":"Theradex - 23","type":"Alternate Question Text","description":"Has patient recovered to less than or equal to grade 1 from the toxicities of these prior therapies, except for stable chronic grade 2 toxicity that is not overlapping with presumed toxicities of olaparib?","url":null,"context":"Theradex"},{"name":"Theradex - 25","type":"Alternate Question Text","description":"Has patient recovered to less than or equal to grade 1 NCI Common Terminology Criteria for Adverse Events (CTCAE) or stabilized from toxicity of prior chemotherapy or biologic therapy administered more than 4 weeks or 5 half-lives earlier, whichever is shorter?","url":null,"context":"Theradex"},{"name":"Theradex - 26","type":"Alternate Question Text","description":"If patient has received prior anti-cancer treatments (i.e. chemotherapy, including gemcitabine and nab-paclitaxel; radiotherapy; hormonal, or immunotherapy with the exception of anti-CTLA4, anti-PD1/PD-L1, and combination of anti-CTLA4 and anti-PD1/PD-L1), have toxicities (except for alopecia) related to prior anti-cancer therapy and/or surgery either resolved, improved to baseline or grade 1?","url":null,"context":"Theradex"},{"name":"Theradex - 27","type":"Alternate Question Text","description":"Has patient recovered from the effects of any prior systemic therapy, radiotherapy or surgery?","url":null,"context":"Theradex"},{"name":"Theradex - 29","type":"Alternate Question Text","description":"Has patient recovered to baseline or less than or equal to Common Terminology Criteria for Adverse Events (CTCAE) v5.0 grade 1 from toxicities related to any prior treatments, unless AE(s) are clinically non-significant and/or stable on supportive therapy?","url":null,"context":"Theradex"},{"name":"Theradex - 28","type":"Alternate Question Text","description":"Have toxicities from prior therapies recovered to less than or equal to grade 1, with the exception of stable chronic grade 2 toxicities that are not overlapping with presumed toxicities of olaparib?","url":null,"context":"Theradex"},{"name":"Theradex - 30","type":"Alternate Question Text","description":"Has patient recovered from toxicities of any prior treatment regimen?","url":null,"context":"Theradex"},{"name":"Theradex - 5","type":"Alternate Question Text","description":"Has patient recovered from the acute toxic effects of prior therapy to a grade 1 (CTCAE v.5.0) level prior to enrollment (does not apply to alopecia)?","url":null,"context":"Theradex"},{"name":"Theradex - 31","type":"Alternate Question Text","description":"Has patient recovered from all non-hematologic toxicities of prior chemotherapy, surgery, or radiotherapy, except alopecia, using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), to less than or equal to grade 1, prior to starting therapy?","url":null,"context":"Theradex"},{"name":"Theradex - 33","type":"Alternate Question Text","description":"Have therapy-related toxicities resolved to less than or equal to Grade 1 or baseline as per the judgement of the treating investigator (with the exception of alopecia, peripheral neuropathy, or rash that will be permitted at less than or equal to Grade 2)?","url":null,"context":"Theradex"},{"name":"Theradex - 32","type":"Alternate Question Text","description":"Has patient not recovered from adverse events from prior cancer therapy (greater than grade 1), except for: alopecia (any grade), neuropathy greater than grade 2?","url":null,"context":"Theradex"},{"name":"COG CRF Text 100","type":"Alternate Question Text","description":"Has the patient recovered from the acute toxicities of any prior therapy?","url":null,"context":"COG"},{"name":"Theradex - 34","type":"Alternate Question Text","description":"Has patient recovered to eligibility levels from prior toxicity?","url":null,"context":"Theradex"},{"name":"Theradex - 35","type":"Alternate Question Text","description":"Has patient recovered from the acute toxic effects of all prior anti-cancer therapies (with the exception of alopecia and lymphopenia)?","url":null,"context":"Theradex"},{"name":"COG CRF Text 1","type":"Alternate Question Text","description":"Has the patient fully recovered from the acute toxic effects of all chemotherapy, immunotherapy, or radiotherapy prior to enrollment?","url":null,"context":"COG"},{"name":"Theradex - 36","type":"Alternate Question Text","description":"Has patient recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities greater than Grade 1) with the exception of alopecia?","url":null,"context":"Theradex"},{"name":"Theradex - 37","type":"Alternate Question Text","description":"Has patient recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities less than or equal to Grade 1 or baseline)?","url":null,"context":"Theradex"},{"name":"Theradex - 40","type":"Alternate Question Text","description":"Has patient recovered from adverse events of previously administered therapeutic agents to Grade 2 or less toxicity according to CTCAE 5.0?","url":null,"context":"Theradex"},{"name":"Theradex - 39","type":"Alternate Question Text","description":"If patient has received chemotherapy, have they recovered (Common Terminology Criteria for Adverse Events [CTCAE] Grade less than or equal to 1) from the acute effects of chemotherapy except for residual alopecia or Grade 2 peripheral neuropathy prior to randomization?","url":null,"context":"Theradex"},{"name":"Theradex - 38","type":"Alternate Question Text","description":"If patient received prior chemotherapy, has the patient recovered (Common Terminology Criteria for Adverse Events [CTCAE] Grade less than or equal to1) from the acute effects of chemotherapy except for residual alopecia or Grade 2 peripheral neuropathy prior to randomization?","url":null,"context":"Theradex"},{"name":"Theradex - 43","type":"Alternate Question Text","description":"Has patient recovered to less than or equal to Grade 1 or baseline of any toxicities due to prior systemic treatments, excluding alopecia?","url":null,"context":"Theradex"},{"name":"Theradex - 42","type":"Alternate Question Text","description":"Has patient recovered from adverse events due to agents administered more than 4 weeks earlier?","url":null,"context":"Theradex"},{"name":"Theradex - 41","type":"Alternate Question Text","description":"Has patient fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to study enrollment?","url":null,"context":"Theradex"},{"name":"Theradex - 44","type":"Alternate Question Text","description":"Have any therapy-related toxicities resolved to less than or equal to Grade 1 or baseline (with the exception of alopecia, peripheral neuropathy, or rash that will be permitted at less than or equal to Grade 2)?","url":null,"context":"Theradex"},{"name":"Theradex - 45","type":"Alternate Question Text","description":"Has patient recovered to eligibility levels from prior toxicity or adverse events?","url":null,"context":"Theradex"},{"name":"Theradex - 46","type":"Alternate Question Text","description":"If patient has received palliative radiotherapy, have they recovered from any radiotherapy related adverse events (allow at least 3 days between radiotherapy completion and study treatment)?","url":null,"context":"Theradex"},{"name":"Theradex - 47","type":"Alternate Question Text","description":"Has patient recovered from clinically significant side effects from prior cancer therapy to grade 1 or below?","url":null,"context":"Theradex"},{"name":"Theradrex - 49","type":"Alternate Question Text","description":"Has patient recovered (CTCAE Grade less than or equal to 1) from the acute effects of chemotherapy except for residual alopecia or Grade 2 peripheral neuropathy prior to enrollment?","url":null,"context":"Theradex"},{"name":"Theradex - 48","type":"Alternate Question Text","description":"Has patient fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to initiation of study treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 50","type":"Alternate Question Text","description":"Has patient recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities less than or equal to Grade 1) with the exception of alopecia or anorexia?","url":null,"context":"Theradex"},{"name":"Theradex - 51","type":"Alternate Question Text","description":"Has patient recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > Grade 1), with the exception of alopecia?","url":null,"context":"Theradex"},{"name":"Alliance text -1","type":"Alternate Question Text","description":"If Yes, has the patient fully recovered from any acute toxicities?","url":null,"context":"Alliance"},{"name":"CCTG_01","type":"Alternate Question Text","description":"Patient has no ongoing toxicity from prior PRRT that is Grade 3 or higher according to CTCAE 5.0.","url":null,"context":"CCTG"},{"name":"Theradex - 52","type":"Alternate Question Text","description":"Has patient recovered to grade 1 or baseline from any toxicities?","url":null,"context":"Theradex"},{"name":"Theradex - 53","type":"Alternate Question Text","description":"Has patient recovered from any clinically relevant toxic effects of any prior surgery, radiotherapy, or chemotherapy treatment with temozolomide?","url":null,"context":"Theradex"},{"name":"Theradex - 54","type":"Alternate Question Text","description":"Has patient recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > Grade 1), with the exception of alopecia or as otherwise specified in the eligibility criteria?","url":null,"context":"Theradex"}],"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"229DF856-5B02-8433-E050-BB89AD436878","latestVersionIndicator":"Yes","beginDate":"2015-10-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2015-10-21","modifiedBy":"SOKKERL","dateModified":"2023-11-20","changeDescription":"10/23/15: Approved and released-tt._10/21/15 protocol 9878/tt.","administrativeNotes":"12/21/22 added AQT and alt OID, CCTG for ticket number CADSR0001818 cjl.","unresolvedIssues":null,"deletedIndicator":"No"}}